ClariVein™ Catheter for Varicose Veins: Clinical Trial Results to be Presented by Dr. Steve Elias

Sept. 9, 2009 - PRLog -- ClariVein™ Catheter for Varicose Veins: Clinical Trial Results to be Presented by Dr. Steve Elias of Englewood Hospital in New Jersey and Mt Sinai in New York City
Dr. Elias is the First Doctor to Test This Device
(Dr. Elias is able to visually show how this device works, please to set up interview)

Englewood Cliffs, New Jersey- September 1, 2009 — The results of the initial clinical trial of the ClariVein™ catheter, used in a new minimally invasive treatment for varicose veins, will be delivered on Wednesday, September 2, at the XVIth World Meeting of the Union Internationale de Phlebologie in Monaco. The device combines mechanical and chemical modalities to accomplish vein treatment in an in-office setting.

Speaking is Steve Elias MD FACS FACPh, Associate Professor of Surgery at Mount Sinai Hospital, NY and the Director of The Centers for Vein Disease at Mount Sinai and Englewood Hospitals. Dr. Elias is the principle investigator of the trial, which was conducted at Englewood Hospital and Medical Center, NJ. Thirty patients were studied in this IRB-regulated trial. This was the first human trial done in the world.

“Initial results are very encouraging,” Dr. Elias states. “The success rates are equal to the early results of radiofrequency or laser treatment of great saphenous vein disease. The main advantage is that the technique does not require tumescence anesthesia infusion, thus saving significant time and decreasing patient discomfort. In addition, no generator is required and capital and maintenance cost is reduced. This in-office procedure takes about 15 minutes to perform and patients walk out of the office resuming normal activity that day.”

The ClariVein™ catheter is a product of Vascular Insights LLC (http://vascularinsights.com) of Madison, CT. The company engages in the design, development, manufacture, and marketing of medical devices for the minimally invasive treatment of peripheral vascular disease. The company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ClariVein™ for infusion of physician-specified agents in the peripheral vasculature.

Dr. Elias is scheduled to speak at the 9:00 am session in the Prince Pierre room of the Grimaldi Forum in Monaco, France and then again on September 25, 2009 at the Philadelphia at the Eastern Vein Society.

About Steve Elias, MD, FACS, FACPh

Director, Center for Vein Disease
Mount Sinai School of Medicine NY

Director, Center for Vein Disease
Englewood Hospital and Medical Center NJ

Steve Elias is the Director of The Centers for Vein Disease at Manhattan’s Mount Sinai Medical Center and at Englewood Hospital and Medical Center in New Jersey is Board Certified in both Phlebology and Surgery.  Dr. Steve Elias was recently named by Vein Magazine as one of the 25 most influential professionals in vein care worldwide and Voted “Best Doctor” in 2009 by New York Magazine.  Dr. Elias lectures, publishes, and teaches extensively about minimally invasive vein care and procedures. As Course Director of the Annual Vascular Fellows Course in Venous Disease, he trains young vascular surgeons in the treatment of vein problems. His clinical interests encompass all aspects of vein care: spider veins, varicose veins, perforator and deep venous incompetence, and venous ulcers. He performs all minimally invasive vein procedures and his work at the Center for Vein Disease includes the prevention and treatment of DVT Deep Venous Thrombosis. Dr. Elias is a fellowship-trained vascular surgeon and member of the American Venous Forum, the American College of Phlebology, the Society for Clinical Vascular Surgery, and the International Society of Cardiovascular Surgery. He is a recipient of the Dardik Research and Education Award.

For Press information contact: Angela Thomas: (201) 503-1333

# # #

Prana Markeitng is a media relations firm focusing on all aspects of entertainment, medical and fashion.